SMC Radiation Oncology SABR Cohort for Oligometastasis

Launched by SAMSUNG MEDICAL CENTER · Aug 8, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well a special type of focused radiation treatment, called stereotactic body radiotherapy (SABR), works for people whose cancer has spread but only to a few spots (up to five). The study wants to see if this treatment can control the cancer, how it affects patients’ quality of life, and whether it causes any side effects. Researchers will also study changes in tiny bits of tumor DNA found in the blood to better understand how the cancer responds to treatment.

People who may join the study are adults between the ages of 65 and 74 who have been diagnosed with metastatic cancer that has spread to a limited number of sites and are in good overall health (able to carry out daily activities with little or no assistance). To be eligible, patients shouldn’t have had radiation in the areas planned for treatment and should not have brain metastases. Participants can expect to receive SABR treatment targeted at their cancer spots and will be closely monitored for how well the treatment works and how it affects their wellbeing. This study is currently enrolling patients and aims to provide helpful information for improving care for people with limited cancer spread.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Performance status (ECOG PS) 0-2
• • Diagnosed with metastatic disease
• • Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)
• Exclusion Criteria:
• • Patient with a history of prior radiotherapy to the site planned for SABR
• • Patients with concomitant brain metastases